Results for tag: "Krabbe Disease Drug"

Krabbe Disease is a rare, inherited disorder of the central nervous system caused by a deficiency of the enzyme galactocerebrosidase. This deficiency leads to the accumulation of toxic substances in the brain and spinal cord, resulting in progressive neurological damage. Treatment for Krabbe Disease is limited to supportive care and enzyme replacement therapy. The Krabbe Disease Drug market is a small but growing segment of the Central Nervous System Drugs market. Currently, there are only a few drugs approved for the treatment of Krabbe Disease, and most of these are enzyme replacement therapies. These drugs are typically administered intravenously and are used to replace the missing enzyme in the body. The Krabbe Disease Drug market is expected to grow in the coming years as more drugs are developed and approved for the treatment of this rare disorder. Companies such as Genzyme Corporation, Shire Pharmaceuticals, and Sanofi-Aventis are actively involved in the development of new drugs for the treatment of Krabbe Disease. Show Less Read more